	US 11,806,389 B2
	Compositions and methods for treating central nervous system injury
Stephen Tomlinson, Charleston, SC (US); DeAnna Adkins, Charleston, SC (US); and Ali Alawieh, Charleston, SC (US)
Assigned to MUSC Foundation For Research Development, Charleston, SC (US); and United States Government as Represented by the Department of Veteran Affairs, Washington, DC (US)
Filed by MUSC Foundation For Research Development, Charleston, SC (US); and United States Government as Represented by the Department of Veteran Affairs, Washington, DC (US)
Filed on May 14, 2021, as Appl. No. 17/320,410.
Application 17/320,410 is a division of application No. 16/342,853, granted, now 11,007,254, previously published as PCT/US2017/056912, filed on Oct. 17, 2017.
Claims priority of provisional application 62/409,196, filed on Oct. 17, 2016.
Prior Publication US 2021/0369823 A1, Dec. 2, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 38/57 (2006.01); C07K 16/18 (2006.01); A61K 38/17 (2006.01); A61K 38/49 (2006.01); A61P 25/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 38/57 (2013.01) [A61K 38/1709 (2013.01); A61K 38/1725 (2013.01); A61K 38/49 (2013.01); A61P 25/00 (2018.01); C07K 16/18 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01)]

7 Claims

1. A method for treating central nervous system injury in a subject, the method comprising (a) administering to the subject a therapeutically effective amount of a composition comprising a targeted inhibitor molecule comprising a targeting portion and a complement inhibitor, and (b) providing rehabilitation therapy to the subject.